SUMMARY BackgroundMost studies evaluating chronic hepatitis C virus (HCV) natural history have taken the development of cirrhosis as an end-point.

With a cure rate of 95% in patients with HCV infection and ESRD Highlights Sofosbuvir/velpatasvir (SOF/VEL) is approved for patients with HCV infection. There is no dosing recommendation for SOF-based regimens for HCV-infected patients on dialysis. We evaluated SOF/VEL for 12 weeks in HCV-infected patients with end-stage renal disease on dialysis. SOF/VEL was safe and well tolerated, with a cure rate of 95% in our study.

No abstract

Summary To better understand outcomes in postpartum patients who receive peripartum anaesthetic interventions, we aimed to assess quality of recovery metrics following childbirth in a UK‐based multicentre cohort study. This study was performed during a 2‐week period in October 2021 to assess in‐ and outpatient post‐delivery recovery at 1 and 30 days postpartum. The following outcomes were reported: obstetric quality of recovery 10‐item measure (ObsQoR‐10); EuroQoL (EQ‐5D‐5L) survey; global health visual analogue scale; postpartum pain scores at rest and movement; length of hospital stay; readmission rates; and self‐reported complications. In total, 1638 patients were recruited and responses analysed from 1631 (99.6%) and 1282 patients (80%) at one and 30 days postpartum, respectively. Median (IQR [range]) length of stay postpartum was 39.3 (28.5–61.0 [17.7–513.4]), 40.3 (28.5–59.1 [17.8–220.9]), and 35.9 (27.1–54.1 [17.9–188.4]) h following caesarean, instrumental and vaginal deliveries, respectively. Median (IQR [range]) ObsQoR‐10 score was 75 ([62–86] 4–100) on day 1, with the lowest ObsQoR‐10 scores (worst recovery) reported by patients undergoing caesarean delivery. Of the 1282 patients, complications within the first 30 days postpartum were reported by 252 (19.7%) of all patients. Readmission to hospital within 30 days of discharge occurred in 69 patients (5.4%), with 49 (3%) for maternal reasons. These data can be used to inform patients regarding expected recovery trajectories; facilitate optimal discharge planning; and identify populations that may benefit most from targeted interventions to improve postpartum recovery experience.

AUC tau (hr*ng/mL) 10300 (18.1) 7120 (30.7) 150 (127, 176) C max (ng/mL) 1320 (20.0) 582 (36.3) 239 (195,292) LDV/SOF (N=13 d ; Test/Reference) LDV AUC tau (hr*ng/mL) 9300 (34.6) 8530 (60.8) 121 (93.2, 156) Cmax (ng/mL) 531 (28.5) 364 (51.4) 158 (126, 197) GS-331007 AUC tau (hr*ng/mL) 11700 (28.8) 12500 (29.2) 94.0 (82.5, 107) C max (ng/mL) 1000 (23.3) 736 (28.2) 138 (121, 157) a PK parameters presented to 3 significant figures b N=1695 (SOF Ph2/3); N=2113 (LDV/SOF Ph2/3) c N=1 subject received tablet formulation instead of granules d N=1 subject dosed over several hours; both were excluded from the summary statistics